SCHEMBL311037

SCHEMBL311037

COC(=O)c1cccc(C(O)=Cc2ccnc(Cl)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALOX15 P16050 2/20 0.46
KDM6B O15054 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
ROCK1 Q13464 1/20 0.43
HTT P42858 1/20 0.41
RAB9A P51151 5/20 0.41
NPC1 O15118 3/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
SRC P12931 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311036 1.00 KDM4E (0.46) KDM4EL3MBTL1ALOX15KDM6BKDM5C
SCHEMBL12362127 0.80 MAPK10 (0.44) L3MBTL1RAB9ANPC1MEN1CYP1A2
SCHEMBL309586 0.78 KCNQ3 (0.40) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL309585 0.78 KCNQ3 (0.40) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1640789 0.75 GAA (0.52) HTTHPGDSMN1; SMN2ALDH1A1
SCHEMBL1641711 0.74 KCNQ3 (0.44) HTTRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL310067 0.74 RAB9A (0.44) KDM4EL3MBTL1ALOX15KDM6BKDM5C
SCHEMBL7669325 0.72 LOXL2 (0.51) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL3696161 0.72 ALDH1A1 (0.49) KDM4EL3MBTL1ALOX15KDM6BKDM5C
SCHEMBL1127074 0.71 PKM (0.41) SMN1; SMN2MEN1KMT2ASLC40A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 KDM4E 790/4885L3MBTL1 4632/4885ALOX15 4854/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 KDM4E 790/4885L3MBTL1 4632/4885ALOX15 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.